HRSA Warns Sanofi Over Proposed Rebate Model; Alludes to Possible Termination of Pharmaceutical Pricing Agreement (PPA) Read more
SCOTUS Declines to Review Important Appellate Decision Protecting 340B Contract Pharmacy Arrangements in Arkansas Read more
Bristol-Myers Squibb Sues To Implement Rebate Model; AbbVie Adds Grantees To Its Contract Pharmacy Policy Read more
Sanofi Announces Rebate Model; All Eyes on Whether HHS Will Threaten to Terminate It from Medicaid and Medicare Read more
CMS Releases Physician Fee Schedule Final Rule for Calendar Year 2025 with Wins and Losses for Covered Entities Read more
VP of Pharmacy for Positive Impact Health Centers Emily Blaiklock on 340B Generic Drug Program for Rural/Ryan White Clinics WOYM 10-4 Read more
AstraZeneca Will Require Submission of Claims Data to 340B ESP™ for Covered Entities to Designate Single Contract Pharmacy Read more
J&J Will No Longer Offer Up-Front 340B Discounts to DSH CEs for Stelara and Xarelto; Drugmaker Unilaterally Imposing Rebate Model Read more
RWC-340B Signs Onto Joint Letter Providing Draft Guidance on the Inflation Reduction Act (IRA) Read more
Gilead Expands Claims Submission Requirements to Wholly-Owned Contract Pharmacies; Government Declines to Appeal Genesis Patient Definition Decision; Egwim Steps Down as Director of OPA. Read more
Updated Chart: Pharmaceutical Manufacturer 340B Price Restriction Policies and Exemptions Summary Read more
National Ryan White Clinic Organization Fires Back at Gilead-Funded “Study” Riddled with Inaccuracies, Faulty Assumptions, and Profit-Centered Analysis Read more
Novo Nordisk Tightens Restrictions on 340B Drugs Dispensed by Contract Pharmacies; Organon Becomes the 22nd Manufacturer to Issue Restrictions Read more
Pharmaceutical Manufacturer 340B Price Restriction Policies and Exemptions Summary Chart Updated Read more
RWC-340B Releases Analysis Warning Federal and State Policymakers of Drug Industry Disinformation Campaign Read more
Johnson & Johnson is the 16th Manufacturer to Restrict Access to 340B Prices at Contract Pharmacies Read more
Gilead to Restrict Access to 340B Prices at Contract Pharmacies for Branded Hep-C Drugs; AbbVie Adds Imbruvica to Restrictive Contract Pharmacy Policy Read more
Pfizer and GSK Announce Policies to Restrict Access to 340B Drugs at Contract Pharmacies; Novo Nordisk Modifies Its Policy Read more
Spanberger to HHS: Hold Drug Companies Accountable for Breaking the Law, Crack Down on Illegal Price Hikes Read more
BMS is the 12th Manufacturer to Restrict Access to 340B Prices at Contract Pharmacies; Permits Designation of One Contract Pharmacy for Three Cancer Drugs Read more
UCB Latest Manufacturer to Announce Restrictive Contract Pharmacy Policy; HRSA Issues Statement Regarding Manufacturer Lawsuits Read more
Eighth Circuit Issues Favorable ERISA Preemption Decision that Likely Protects State 340B Anti-Discrimination Laws Read more
Update on 340B Contract Pharmacy Litigation — Decisions Issued in Four Manufacturer Lawsuits Read more
RWC-340B Applauds Court’s “Fairest and Most Reasonable” Interpretation of the 340B Drug Pricing Program: Manufacturer Actions Shall Not Undermine the Safety Net Read more
Boehringer Ingelheim Is Latest Manufacturer to File a Lawsuit Against HHS On Contract Pharmacy Program Read more
Rep. Matt Rosendale Introduces Legislation: DSH 340B Eligibility Moratorium, Regulations Limiting Such Eligibility, and Increased Reporting Requirements Read more
United Therapeutics Seeks Records from HRSA Regarding Covered Entity Compliance with Duplicate Discount and Diversion Prohibitions Read more
HRSA Refers Six Pharmaceutical Manufacturers to HHS-Office of the Inspector General for Imposition of Civil Monetary Penalties Read more
The Parkersburg News and Sentinel – Protect 340B: Legislation needed for lowering drug pricing Read more
Reps. McKinley and Spanberger Introduce Bi-Partisan Federal Legislation to Prohibit Discrimination Against 340B Safety Net Providers by Payers Read more
United Therapeutics Is Latest Manufacturer to File Lawsuit Against HHS On Contract Pharmacy Program Read more
Ryan White Clinics Endorse McKinley-Spanberger Legislation to Prohibit Discrimination Against 340B Safety Net Providers, Protect Program Integrity Read more
Boehringer Ingelheim Latest Manufacturer to Announce It Will No Longer Offer 340B Discounts at Most Contract Pharmacies Read more
House Rep. McKinley Applauds HHS Letters to Manufacturers Condemning Refusal to Honor Contract Pharmacy Arrangements Read more
HRSA Informs Six Manufacturers That Their Contract Pharmacy Policies Violate the 340B Statute Read more
Novo Nordisk and United Therapeutics Are the Latest Drug Manufacturers to Limit Access to 340B Prices at Contract Pharmacies Read more
Press Release: RWC-340B and 340B Covered Entity Plaintiffs Ask Secretary of HHS to Immediately Enforce Covered Entities’ Rights Under 340B Statute Read more
217 Congressional Representatives Send Letter to Secretary Azar Opposing the Kalderos Rebate Model Read more
Sentry Stands with Ryan White Clinics as Study Highlights Importance of Funding and 340B Program in Managing HIV/AIDS Epidemic Read more
Cancer Care and the 340B Program: “People in underserved communities don’t want to be test subjects” Read more
RWC-340B and 340B Grantee Plaintiffs File Lawsuit Against HHS/HRSA to Protect 340B Contract Pharmacy Program from Manufacturer Attacks Read more
Discriminatory Reimbursement Practices by PBMs Represent a Threat to Public Health: A Perspective from Community Health Read more
RWC-340B Submits Letter to HHS Regarding Drug Manufacturers Actions That Undermine the 340B Program & Letter to HRSA Regarding 340B Telehealth Policies Read more
Novartis To Collect Contract Pharmacy Claims Data Through 340B ESP, TPAs and Specialty Pharmacies Express Concern Over Data Submitted Read more
Reps. Matsui and Stewart Introduce Legislation to Protect 340B Hospitals During COVID-19 Pandemic Read more
President Trump Signs Executive Orders on Lowering Drug Prices – Potential Impact for 340B Safety-Net Providers Read more
Recent Actions by Drug Manufacturers Merck and Eli Lilly Pose a Threat to Safety-Net Provider’s Ability to Access Drugs at 340B Prices Read more
Sentry Data Systems joins Ryan White Clinics for 340B Access (RWC-340B) in the fight to protect the nation’s most vulnerable patients Read more
Defense in Congress, Offense in the States: Ryan White Clinics Fighting Against Discriminatory 340B Reimbursement Read more
HRSA/OPA Guidance in Response to COVID-19 and DEA Waiver on Controlled Substance Prescriptions Read more
Presidential Budget Proposes 340B Savings Usage Records, Covered Entity User Fees, and Expanded HRSA Authority Read more
CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and STD Prevention and Treatment Meeting – November 13 & 14 Read more
HRSA to Collect Information Regarding Clients Receiving Non-Funded Outpatient Ambulatory Health Services Read more
Study Finds that Peer-to-Peer Connections Help Individuals with Unsuppressed HIV Get the Care Necessary to Achieve Viral-suppression Read more
RWC-340B Submits Comment Letter to HRSA Contesting Registration Policy for RWCs and STD Clinics Read more
Court Holds 2019 Reimbursement Cuts for 340B Drugs Unlawful; Remands to HHS for Remedy for 2018 and 2019 Read more
Trump Administration’s 2020 Budget Proposal – Significant Changes to 340B, Global HIV/AIDS Funding, and Medicare and Medicaid Read more
CANN National 340B Commission Releases Report Calling for Harmful Changes to the 340B Program Read more
Ask Your Representative to Support Ryan White Clinics by Co-Sponsoring H.R.6071, The SERV Act Read more
RWC-340B Sponsors Congressional Briefing on How and Why 340B Program Works for Minority Populations Read more
Ensuring the Value of the 340B Program Act Threatens Continuum of Care for HIV/AIDS Patients & Future of the 340B Program Read more
RWC-340B Sends Letter to Santa Clara County Board of Supervisors Member Regarding 340B Support Read more
Join RWC-340B to Discuss the State of the 340B Program and the Coalition’s Advocacy Efforts Read more
HRSA Publishes Final Rule Addressing 340B Ceiling Price Calculations and Manufacturer Penalties for Overcharging Read more
RWC-340B Comments on HRSA’s Proposed Regulations to Implement Civil Monetary Penalties on Drug Manufacturers That Overcharge Read more
